Need to keep on high of the science and politics driving biotech in the present day? Join to get our biotech publication in your inbox.
Grail’s Galleri blood take a look at simply failed a make-or-break NHS trial, lacking its major endpoint and reviving the uncomfortable query: Does earlier detection truly change outcomes, or simply the timeline for diagnoses?
And there’s extra information out of the FDA: The company has put in an AI business vet to steer digital well being, and new CDER chief Tracy Beth Høeg tells workers she’s eager to revisit SSRIs in being pregnant and scrutinize RSV monoclonals.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
View All Plans
